Abivax has been granted a patent for a compound, specifically 8-Chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine, aimed at treating various inflammatory diseases. The patent covers conditions affecting multiple organs, including the pancreas, kidneys, liver, lungs, skin, blood vessels, eyes, nervous system, and reproductive system. GlobalData’s report on Abivax gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Abivax, Cancer treatment biomarkers was a key innovation area identified from patents. Abivax's grant share as of June 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
Inflammatory disease treatment using specific compounds
The granted patent US11992499B2 outlines a method for treating various inflammatory diseases, disorders, or conditions through the administration of a specific compound, 8-Chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine, or its pharmaceutically acceptable salts. The claims detail a wide range of inflammatory conditions that can be targeted, including those affecting the pancreas (such as diabetes and pancreatitis), kidneys (like glomerulosclerosis and nephritis), liver (including nonalcoholic steatohepatitis), lungs and heart (such as COPD and myocarditis), skin (like dermatitis and vitiligo), blood vessels (including vasculitis), eyes (such as conjunctivitis), and the nervous system (covering conditions like encephalitis and neuropathic pain). Additionally, the patent addresses autoimmune diseases and inflammatory conditions in the reproductive system and bones/joints.
The patent further specifies methods for monitoring the treatment's efficacy, including measuring the levels of the compound in various biological samples and assessing the expression levels of biomarkers such as miR-124. It also mentions the potential for co-administration with JAK-inhibitors, particularly tofacitinib, to enhance therapeutic outcomes. The claims encompass various formulations of the compound and its combinations, indicating a comprehensive approach to managing inflammatory conditions through targeted pharmacological intervention.
To know more about GlobalData’s detailed insights on Abivax, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
